Clinical Trials Logo

Filter by:
NCT ID: NCT02154646 Completed - Clinical trials for Pancreatic Neoplasms

A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

Start date: May 2014
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and side effects of LY2157299 in combination with gemcitabine in Japanese participants with pancreatic cancer that is advanced or has spread to another part of the body.

NCT ID: NCT02154347 Completed - Clinical trials for Type 2 Diabetes Mellitus

Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

Start date: n/a
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate glycemic control with diet, and insulin monotherapy, or insulin and oral hypoglycemic agent.

NCT ID: NCT02153398 Completed - Clinical trials for Zollinger-Ellison Syndrome

A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases

Start date: June 2014
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old who either have a diagnosis of or are suspected to have gastric ulcer (GU), duodenal ulcer (DU), anastomotic ulcer (AU), non-erosive reflux esophagitis disease (NERD), reflux esophagitis (RE) or Zollinger-Ellison syndrome.

NCT ID: NCT02153086 Completed - Insomnia Clinical Trials

Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Accompanied by Difficulty Falling Asleep> − Transitional Survey From the Preceding Drug-use Survey −

Start date: March 2011
Phase: N/A
Study type: Observational

The purpose of this survey is to examine the safety and efficacy of long-term use of ramelteon tablets (Rozerem 8 mg Tablets) in patients with difficulty falling asleep associated with insomnia in daily medical practice.

NCT ID: NCT02153073 Completed - Hyperlipidemia Clinical Trials

Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters

Start date: May 29, 2013
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in patients with hyperlipidemia in daily medical practice

NCT ID: NCT02152761 Completed - Clinical trials for Muscle Wasting (Atrophy) After Hip Fracture Surgery

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Start date: September 16, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.

NCT ID: NCT02151162 Completed - Anxiety Disorders Clinical Trials

Happy Nurse Project: Lifestyle Interventions to Maintain Healthy Mental State in Hospital Nurses

HNP
Start date: June 11, 2014
Phase: N/A
Study type: Interventional

The study is to explore the effectiveness of omega-3 fatty acids and mindfulness-based stress management program to maintain healthy mental state in hospital nurses. The participants will be junior nurses who work in inpatient wards and are not clinically depressed. The participants will be randomly allocated to four intervention arms: 1) Mindfulness-based stress management program plus omega-3 fatty acids pills ; 2) Mindfulness-based stress management program plus placebo pills; 3) Psychoeducation leaflet plus omega-3 fatty acids pills; and 4) Psychoeducation leaflet plus placebo pills. Thirty participants will be allocated to each arm. These interventions will terminate until three months from registration for each participant. Information about depression and anxiety symptoms (primary outcome), insomnia, burnout, presenteeism, quality of life, sick leave, consultation about mental state of herself, and oxidative stress will be collected at 3 months, 6 months (primary time point) and 12 months from registration for each participant.

NCT ID: NCT02150603 Completed - Clinical trials for Heart Defects, Congenital

Patient-Reported Outcomes in Adults With Congenital Heart Disease

APPROACH-IS
Start date: April 2013
Phase: N/A
Study type: Observational

The purpose of this study is to examine the differences in perceived health, psychosocial functioning, behavioral outcomes and quality of life of adults with congenital heart disease who are living in different areas of the world, and how these differences can be understood (e.g., differences in sense of coherence or illness perceptions).

NCT ID: NCT02149108 Completed - Clinical trials for Colorectal Neoplasms

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Start date: September 2014
Phase: Phase 3
Study type: Interventional

The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.

NCT ID: NCT02148549 Completed - Clinical trials for Patients With Borderline Resectable Pancreatic Cancer

Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study

FIRINOX
Start date: April 2014
Phase: Phase 1
Study type: Interventional

FOLFIRINOX regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer. FOLFIRINOX is one of the high response rate treatment regimen , the investigators considered as a promising treatment as neoadjuvant chemotherapy . On the other hand , incidences of grade 3 or 4 neutropenia , febrile neutropenia and diarrhea were significantly higher in the FOLFIRINOX group compared with gemcitabine group. Therefore, it was decided to consider the balance of safety and efficacy as a preoperative chemotherapy, the investigators use the FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen